US FDA

Lupin Launches Sugammadex Injection in US Following FDA Approval for Bridion Generic

Lupin Limited launches Sugammadex Injection in the US, a bioequivalent to Merck's Bridion® for surgical recovery, as the company reports 62.5% annual profit growth.

Lupin · 31 Jul 2026, 11:15 AM IST